ngiotensin II receptor blockers (ARB) have been shown to improve long-term outcome in patients with hypertension and left ventricular hypertrophy, and recent experimental studies in animal models suggest that ARB could prevent the progression of atherosclerosis and therefore lead to plaque regression. [1] [2] [3] [4] [5] [6] Although Strawn et al found that ARB inhibited fatty-streak formation by protecting low-density lipoprotein (LDL) from oxidation and suppressing vascular monocyte activation in non-human primates, 2 Johnstone et al demonstrated in an animal model that ARB reduce macrophage accumulation and plaque disruption and thereby attenuate the development of atherosclerosis. 3 More recently, 6-month administration of ARB has been reported to reduce the intimal hyperplasia in monkeys with diet-induced hypercholesterolemia. 4 However, the in vivo effects of ARB on Circulation Journal Vol. 70, September 2006 human coronary atherosclerosis have not been previously studied.
in the very proximal LAD or LCX, which could affect LM coronary artery plaque, (7) successful PCI for discrete lesions in the LAD or LCX. Nonostial plaque location in the LAD and LCX was defined as angiographic lumen diameter <30% in the worst view and <50% plaque burden. Patients who had had angiotensin converting enzyme (ACE) inhibitors or ARB were excluded because of the similarity of each drug's action. In the ARB group, all patients received losartan 25-50 mg daily. This study was approved by the local ethics committees and all patients gave their written informed consent.
Following successful PCI, all patients were subsequently treated with a combination of -blockers, calcium-channel blockers, or ARB at the physician's discretion. Patients were subsequently divided into 2 groups (ARB and non-ARB).
PCI and IVUS Procedures
PCI was performed according to standard clinical practice using the trans-radial or trans-femoral approach. 9, 10 IVUS examination (2.5Fr, 40-MHz, Boston Scientific, Fremont, CA, USA) was performed with intracoronary administration of isosorbide dinitrate after successful PCI and at 7-month follow-up. [11] [12] [13] [14] A motorized pull back device (0.5 mm/s) was used for IVUS data acquisition 13, 14 and all IVUS images were recorded on S-VHS videotape for subsequent off-line analysis.
IVUS Measurements
The serial IVUS analysis was performed at an independent core laboratory of Aichi Medical University by 2 experienced investigators who were unaware of the medical treatment groups. Cross-sectional luminal area (LA) was defined as the integrated area central to the intimal leading edge echo. [14] [15] [16] The total vessel cross-sectional area (VA) was defined as the area inside the interface between the plaque -media complex and adventitia (area inside the external elastic membrane) and plaque area was defined as VA -LA. [14] [15] [16] We measured vessel volume and lumen volume using an algorithm based on Simpson's rule. 15, 17 Plaque volume was calculated as vessel volume minus lumen volume. 17 von Birgelen et al reported that plaque progession and regression in the LM coronary artery were significantly related to serum cholesterol changes and clinical events, 7,8 so we estimated the plaque volume changes (delta PV) as an indicator of coronary atherosclerosis progression. Volumetric analysis throughout the LM coronary artery was performed with a Netra 3D IVUS system (ScImage, Los Altos, CA, USA). 17 To obtain 2 identical analysis segments of the LM coronary artery at baseline and follow-up IVUS studies, we displayed the baseline and follow-up IVUS images side-by-side and used serial IVUS video sequences, together with information about the motorized pullback speed, the operator's recorded comments, and landmarks such as the presence of calcium deposits, side branches, plaque shape, and vascular and perivascular structures. Given that volume index (VI) was calculated as volume divided by the length of the vessel (VVI), lumen (LVI), and plaque (PVI), the VI is reported in mm 2 (= mm 3 /mm).
The reliability of the IVUS measurement system was quantified using a vessel phantom model as previously described. 14, [18] [19] [20] In brief, the correlation between true phantom volume and IVUS volume measurements was 0.99, the mean difference (accuracy) of the 2 volumes was -2.23 mm 3 in the 5-20 mm length phantom (average length 12.5 mm); the accuracy of the VI (per 1 mm) was -0.17 mm 2 , and the standard deviation (precision) was 0.10 mm 3 in the validation study.
Statistic Analysis
Data were analyzed using the SAS statistical software package (SAS Institute, Cary, NC, USA). All continuous values are expressed as mean ± SD. Differences in categorical variables between the non-ARB group and ARB group were assessed using the chi-square test. The unpaired t-test was used to assess differences in continuous variables between the 2 groups. Differences between baseline and follow-up were assessed with Student's paired t-test. A value of p<0.05 was considered statistically significant.
Results

Baseline Clinical Characteristics
A total of 64 patients were enrolled in this observational study (non-ARB group: 41 patients; ARB group: 23 patients). No significant difference was observed in the baseline clinical characteristics of the 2 groups (Table 1) . The follow-up duration was also similar (non-ARB: 7.3±2.5 months; ARB: 7.5±3.0 months, p= NS) ( Table 1 ). There was no significant difference in blood pressure or serum lipid level between the 2 groups both at baseline and at follow-up (Table 2) . Table 3 summarizes the medication status of the patients. None of the patients had had ACE inhibitors in accordance with the inclusion criteria of the study. In the ARB group, 10 patients had 25 mg losartan daily and the remaining 13 received 50 mg daily (mean dose 39.1±12.7 mg). The number of patients taking calciumchannel blockers was significantly greater in the non-ARB group than in the ARB group. Rates of use of -blockers, aspirin, statins and oral hypoglycemic drugs were also similar between the 2 groups.
IVUS Findings
Volumetric IVUS analysis indicated no baseline differences between the non-ARB and ARB groups in VVI (non-ARB 23.4±5.5 mm 2 vs ARB 24.2±5.2 mm 2 , p=NS), LVI (non-ARB 14.4±4.4 mm 2 vs ARB 14.3±4.3 mm 2 , p=NS) and PVI (non-ARB 9.0±3.0 mm 2 vs ARB 9.9±3.1 mm 2 , p=NS). Whereas the non-ARB group did not show a significant chronological change in VVI, LVI, and PVI, the ARB group exhibited a significant decrease in PVI during follow-up (baseline 9.9±3.1 mm 2 vs follow-up 9.1±2.7 mm 2 , p<0.01) ( Table 4 ). The delta VVI was similar between the 2 groups, delta LVI tended to be greater in the ARB (lumen gain) in comparison with the non-ARB group (Fig 1) . Subsequently, delta PVI was significantly lower in the ARB group than that in the non-ARB group (Fig 1) .
Discussion
The results reveal that use of ARB may retard progression of atherosclerotic plaques and stimulate plaque regression in patients with IHD.
Renin-Angiotensin-Aldosterone Axis and Progession of Coronary Atherosclerosis
The renin-angiotensin-aldosterone axis plays a critical role in the pathogenesis of cardiovascular disease. 21 Angiotensin II stimulates intracellular pathways that promote atherosclerosis through inflammation, endothelial dysfunction, proliferation, fibrosis and thrombosis. [21] [22] [23] Animal studies have shown that inhibition of the renin-angiotensin system suppresses proliferation of smooth muscle cells and prevents atherosclerosis progression. 2, 24, 25 ARB inhibit the renin-angiotensin system more selectively than ACE inhibitors, therefore the administration of ARB could be a favorable strategy for preventing plaque progression.
IVUS-Detected LM Coronary Artery Plaque Burden and Cardiovascular Event Risk
Our IVUS findings suggest that the administration of 
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ARB is associated with a reduction in coronary plaque burden during follow-up. Von Birgelen et al have recently reported the close relationship between adverse cardiac event-risk and plaque progression in the LM coronary artery measured by IVUS. 7, 8 Although it has already been shown that ARB improve long-term outcome in patients with hypertension and left ventricular hypertrophy, ARB that could improve plaque burden in the coronary artery would convey a more favorable long-term outcome in patients with coronary atherosclerosis. 1 Although randomized studies have demonstrated that ARB improves cardiovascular morbidity and mortality in patients with hypertension or heart failure and reduces cerebrovascular events in patients with cerebral ischemia or hypertension, several studies have failed to show an advantage to using these agents with regard to the prevention of myocardial infarction (MI). 1, [26] [27] [28] In the Study of Cognition and Prognosis in the Elderly (SCOPE), candesartan was associated with a non-significant but worrying trend towards an increase in MI, despite the 3.2-mmHg lower systolic blood pressure achieved relative to placebo. 29 Furthermore, the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study did not reduce rates of MI despite lowering blood pressure 1.7 mmHg more than the comparator atenolol. 1 In the VALUE study, valsartan failed to prevent the occurrence of MI in comparison with amlodipine, although heart failure was more effectively suppressed by valsartan than by amlodipine. 26 It has long been recognized that MI occasionally occurs in mildly to moderately stenosed vessels, where the most severe stenosis is less than 50%, the so-called jump-up phenomenon. 30 A possible explanation for this is that the underlying mechanism responsible for the occurrence of MI might differ substantially from that responsible for the progression of coronary atherosclerosis.
Possible Role of ARB in the Progression and Regression of Coronary Atherosclerosis
Strawn et al demonstrated for the first time an antiatherogenic effect of ARB in non-human primates. ARB (losartan) inhibited fatty-streak formation through mechanisms that may include protection of LDL from oxidation and suppression of vascular monocyte activation and recruitment factors. 2 Johnstone et al recently found that ARB (candesartan) in a rabbit model reduced macrophage accumulation, increased collagen deposition within the plaque, reduced the frequency of plaque disruption and thereby attenuated the development of atherosclerosis. 3 ARBs have been reported to decrease macrophage accumulation and chemokine expression, and attenuate LDL oxidation. 31, 32 The doses of ARB used in those animal models were far greater than those used in clinical practice, raising doubts about whether the resultant findings can be directly extrapolated to humans. More recently, Takai et al reported for the first time that 6-month administration of ARB (olmesartan) in a monkey model reduced the carotid -artery intimal hyperplasia caused by 6-month high-cholesterol diet. 4 Their experimental dose of ARB did not affect blood pressure or plasma cholesterol levels throughout the experimental study and nor did our dose alter either blood pressure or serum cholesterol levels during the follow-up period.
Despite such circumstantial evidence, it has not yet been established whether ARB can alter the process responsible for the progression of coronary atherosclerosis in humans. Our study lends support to the idea that ARB can retard the progression of atherosclerosis and facilitate plaque regression for the first time in humans with IHD.
Study Limitations
First, the number of patients undergoing serial volumetric IVUS analysis was small. A larger patient population with longer follow-up periods and serial IVUS studies is required to delineate the precise relationship between the administration of ARB, plaque progression and regression, and cardiovascular events. Second, the study was not randomized according to ARB or non-ARB arms, which raises the possibility of selection bias, although no special attention was paid concerning the selection of ARB or non-ARB arm during enrolment for the study. Finally, the administration of statins and the cholesterol level would affect progression of coronary atherosclerosis. Because no difference was found in the use of statins in the ARB and non-ARB groups (ARB 52%, non-ARB 51%), or in the cholesterol levels between the 2 groups (Table 2) , it is theoretically assumed that statin and cholesterol levels contributed equally to the process of atherosclerosis in the 2 groups. In fact, no significant relationship was found between delta PV and total cholesterol level changes (r=0.073, p=NS), delta PV and delta triglyceride (r=0.043, p=NS), delta PV and delta high-density lipoprotein (r=0.091, p=NS), and delta PV and delta LDL (r=0.016, p=NS).
Conclusions
This preliminary study indicates that long-term administration of ARB could contribute to the prevention of the progression of coronary atherosclerosis in patients with significant atherosclerotic disease. A long-term randomized follow-up study using ARB is needed to confirm the validity of these findings in a larger patient population with IHD.
